25: PTC Online Resource Library

25: PTC Online Resource Library

Updated: 2/14/2022

There are many resources available online about all aspects of cancer (fewer specifically devoted to post-transplant risks, but other information would still be applicable for post-transplant issues), MANY (literally 100's) of which are listed here:

PTC Resources: Site links, videos, articles, and so much more . . .


TRIO Full-length Cancer-related Videos by our PTC medical faculty:

The TRIO Transplant Presentation Library features many full-length post-transplant cancer presentations by medical staff that are available on YouTube.  Most are either one-on-one interviews or support group presentations, some over an hour in length as transplant recipients in the audience question, and engage in discussion with these noted presenters. Segments from these recordings are found throughout this PTC website in support of appropriate subject pages.  They are listed here for further access convenience, duplicating their listing in that Transplant Presentation Library index which can be found along with over 100+ transplant-related videos that are not cancer-focused, but of patient interest.Cancer researchers Note: the indexed/topic-searchable full TRIO Transplant Presentation Library is available at https://www.trioweb.org/resources/transplant-presentation-library-dvd-program.html

TRIO Post-transplant Cancer workshop slide set:
Slides used at 2016 TGA (Transplant Games of America) PTC workshop

The AJT (American Journal of Transplantation) ran a 12‐month series of articles about cancer, a major complication of solid organ transplantation and gave TRIO public access so they could be offered here:

 NCI Dictionary of Cancer Terms
The NCI Dictionary of Cancer Terms features 8,545 terms related to cancer and medicine.


Directory of clinical trials:
> NIH: ClinicalTrials.gov
> National Cancer Institute clinical trials search tool
> PTLD Clinical Trials fact sheet

Cancer Support Groups:
> AICR contact listing of support groups by cancer type
> Lung Cancer Center

Cancer general resources:

Cancer articles & videos of interest:


Immunosuppressant drugs:

  • Calcineurin inhibitors:
    Gengraf, Neoral,  Sandimmune (generic name: cyclosporine)
    Hecoria, Prograf, Astagraf XL (generic name: tacrolimus)

  • mTOR inhibitors:
    Afinitor, Afinitor Disperz, Zortress (generic name: everolimus)
    Torisel (generic name: temsirolimus)
    Rapamune (generic Name: sirolimus)

Cancer in Transplant Recipients:

Skin cancer resources:

Kidney cancer resources:

Financing for Fighting Cancer:

Blood cancer resources:

Immunosuppression/Immunodeficiency and Cancerlibrary scene:

 Publications from the Transplant Cancer Match Study:

(click on the title above to learn more about this collaborative study that produced the papers listed below)

  1. Morton LM, Gibson TM, Clarke CA, Lynch CF, Anderson LA, Pfeiffer R, Landgren O, Weisenburger DD, Engels EA. Risk of myeloid neoplasms after solid organ transplantationLeukemia. 2014 Dec;28(12):2317-23.
  2. Wetmore JB, Calvet JP, Yu AS, Lynch CF, Wang CJ, Kasiske BL, Engels EA. Polycystic kidney disease and cancer after renal transplantationJ Am Soc Nephrol. 2014 Oct;25(10):2335-41.
  3. Koshiol J, Pawlish K, Goodman MT, McGlynn KA, Engels EA. Risk of hepatobiliary cancer after solid organ transplant in the United StatesClin Gastroenterol Hepatol. 2014 Sep;12(9):1541-9.
  4. Gibson TM, Engels EA, Clarke CA, Lynch CF, Weisenburger DD, Morton LM. Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United StatesAm J Hematol. 2014 Jul;89(7):714-20.
  5. Engels EA, Castenson D, Pfeiffer RM, Kahn A, Pawlish K, Goodman MT, Nalesnik MA, Israni AK, Snyder J, Kasiske B. Cancers among US organ donors: a comparison of transplant and cancer registry diagnosesAm J Transplant. 2014 Jun;14(6):1376-82.
  6. Morton LM, Gibson TM, Clarke CA, Lynch CF, Weisenburger DD, Engels EA. Hepatitis B or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant recipientsHaematologica. 2014 May;99(5):70-3.
  7. Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the United StatesAm J Transplant. 2013 Dec;13(12):3202-9.
  8. Hall EC, Engels EA, Montgomery RA, Segev DL. Cancer risk after ABO-incompatible living-donor kidney transplantationTransplantation. 2013 Sep 15;96(5):476-9.
  9. Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martínez-Maza O, Hussain SK, Yang J, Chang ET, Engels EA. Risk of lymphoma subtypes after solid organ transplantation in the United StatesBr J Cancer. 2013 Jul 9;109(1):280-8.
  10. Engels EA, Clarke CA, Pfeiffer RM, Lynch CF, Weisenburger DD, Gibson TM, Landgren O, Morton LM. Plasma cell neoplasms in US solid organ transplant recipientsAm J Transplant. 2013 Jun;13(6):1523-32.
  11. Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantationCancer. 2013 Jun 15;119(12):2300-8.
  12. Mbulaiteye SM, Clarke CA, Morton LM, Gibson TM, Pawlish K, Weisenburger DD, Lynch CF, Goodman MT, Engels EA. Burkitt lymphoma risk in U.S. solid organ transplant recipientsAm J Hematol. 2013 Apr;88(4):245-50.
  13. Hall EC, Segev DL, Engels EA. Racial/ethnic differences in cancer risk after kidney transplantationAm J Transplant. 2013 Mar;13(3):714-20.
  14. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipientsJAMA. 2011 Nov 2;306(17):1891-901.

Post-transplant Cancer References
(from an article at https://jamanetwork.com/journals/jama/fullarticle/1104578 )

1. US Department of Health and Human Services.  Organ Procurement and Transplantation Network. http://optn.transplant.hrsa.gov/. Accessed May 5, 2011
2. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation.  Int J Cancer. 2009;125(8):1747-175419444916PubMedGoogle ScholarCrossref
3. Birkeland SA, Storm HH, Lamm LU,  et al.  Cancer risk after renal transplantation in the Nordic countries, 1964-1986.  Int J Cancer. 1995;60(2):183-1897829213PubMedGoogle ScholarCrossref
4. Collett D, Mumford L, Banner NR,  et al.  Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit.  Am J Transplant. 2010;10(8):1889-189620659094PubMedGoogle ScholarCrossref
5. Villeneuve PJ, Schaubel DE, Fenton SS,  et al.  Cancer incidence among Canadian kidney transplant recipients.  Am J Transplant. 2007;7(4):941-94817331115PubMedGoogle ScholarCrossref
6. Vajdic CM, McDonald SP, McCredie MR,  et al.  Cancer incidence before and after kidney transplantation.  JAMA. 2006;296(23):2823-283117179459
ArticlePubMedGoogle ScholarCrossref


Adami J, Gäbel H, Lindelöf B,  et al.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.  Br J Cancer. 2003;89(7):1221-122714520450PubMedGoogle ScholarCrossref


Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population.  Transpl Int. 2000;13:(suppl 1)  S394-S39811112040PubMedGoogle ScholarCrossref


Serraino D, Piselli P, Angeletti C,  et al.  Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients.  Br J Cancer. 2005;92(3):572-57515668710PubMedGoogle Scholar


Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States.  Am J Transplant. 2004;4(6):905-91315147424PubMedGoogle ScholarCrossref


Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.  Lancet. 2007;370(9581):59-6717617273PubMedGoogle ScholarCrossref


Bouvard V, Baan R, Straif K,  et al; WHO International Agency for Research on Cancer Monograph Working Group.  A review of human carcinogens—part B: biological agents.  Lancet Oncol. 2009;10(4):321-32219350698PubMedGoogle ScholarCrossref


Chaturvedi AK, Mbulaiteye SM, Engels EA. Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers.  Ann Epidemiol. 2008;18(3):230-23418083545PubMedGoogle ScholarCrossref


Breslow NE, Day NE. The Design and Analysis of Cohort Studies. Vol II. Lyon, France: International Agency for Research on Cancer; 1987


Surveillance, Epidemiology and End Results Program.  SEER*Stat Database: Incidence - SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases. http://seer.cancer.gov/data/metadata.html. Accessed May 5, 2011


Kasiske BL, Vazquez MA, Harmon WE,  et al; American Society of Transplantation.  Recommendations for the outpatient surveillance of renal transplant recipients.  J Am Soc Nephrol. 2000;11:(suppl 15)  S1-S8611044969PubMedGoogle Scholar


Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma.  Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765-177717035381PubMedGoogle ScholarCrossref


Swindle P, Falk M, Rigby R,  et al.  Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics.  Br J Urol. 1998;81(2):229-2339488064PubMedGoogle ScholarCrossref


Layman AB, Engels EA. Kidney and bladder cancers among people with AIDS in the United States.  J Acquir Immune Defic Syndr. 2008;48(3):365-36718580342PubMedGoogle ScholarCrossref


Harris NL, Swerdlow SH, Frizzera G, Knowles DM. Post-transplant lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:264-269


van Leeuwen MT, Grulich AE, Webster AC,  et al.  Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation.  Blood. 2009;114(3):630-63719443660PubMedGoogle ScholarCrossref


Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand.  Transplantation. 2005;80(2):193-19716041263PubMedGoogle ScholarCrossref


Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States.  Am J Hematol. 2011;86(2):206-20921264909PubMedGoogle ScholarCrossref


Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder.  Transpl Infect Dis. 2001;3(2):70-7811395972PubMedGoogle ScholarCrossref


Andreone P, Gramenzi A, Lorenzini S,  et al.  Posttransplantation lymphoproliferative disorders.  Arch Intern Med. 2003;163(17):1997-200414504111
ArticlePubMedGoogle ScholarCrossref


Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report.  Am J Transplant. 2004;4(2):222-23014974943PubMedGoogle ScholarCrossref


Minai OA, Shah S, Mazzone P,  et al.  Bronchogenic carcinoma after lung transplantation: characteristics and outcomes.  J Thorac Oncol. 2008;3(12):1404-140919057264PubMedGoogle ScholarCrossref


Dickson RP, Davis RD, Rea JB, Palmer SM. High frequency of bronchogenic carcinoma after single-lung transplantation.  J Heart Lung Transplant. 2006;25(11):1297-130117097492PubMedGoogle ScholarCrossref


Ritchie AJ, Mussa S, Sivasothy P, Stewart S. Single-lung transplant complicated by unexpected explant carcinoma: a management dilemma.  J Heart Lung Transplant. 2007;26(11):1206-120818022089PubMedGoogle ScholarCrossref


Abrahams NA, Meziane M, Ramalingam P,  et al.  Incidence of primary neoplasms in explanted lungs.  Transplant Proc. 2004;36(9):2808-281115621155PubMedGoogle ScholarCrossref


Engels EA. Inflammation in the development of lung cancer: epidemiological evidence.  Expert Rev Anticancer Ther. 2008;8(4):605-61518402527PubMedGoogle ScholarCrossref


Thuluvath PJ, Guidinger MK, Fung JJ,  et al.  Liver transplantation in the United States, 1999-2008.  Am J Transplant. 2010;10(4 pt 2):1003-101920420649PubMedGoogle ScholarCrossref


Mazzaferro V, Regalia E, Doci R,  et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;334(11):693-6998594428PubMedGoogle ScholarCrossref


Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.  Transplantation. 2008;86(6):784-79018813102PubMedGoogle ScholarCrossref


Goh A, Vathsala A. Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients.  Am J Transplant. 2011;11(1):86-9220973916PubMedGoogle ScholarCrossref


Heinz-Peer G, Schoder M, Rand T,  et al.  Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study.  Radiology. 1995;195(3):667-6717753991PubMedGoogle Scholar


de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.  Am J Kidney Dis. 2000;35(2):333-34610676738PubMedGoogle ScholarCrossref


Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.  Transplantation. 2004;77(12):1777-178215223891PubMedGoogle ScholarCrossref


Welch HG, Black WC. Overdiagnosis in cancer.  J Natl Cancer Inst. 2010;102(9):605-61320413742PubMedGoogle ScholarCrossref

Choose a resource for more information:

Follow TRIO on  

Sponsors & Supporters

  • Gift of Life Donor Program
  • CareDx
  • Atara Bio
  • GuideStar 2020 Platinum
  • UNOS
  • AAKP
  • Clinical Consulting Associates
  • GLI
  • Notion design sponsor
  • solicitation
    17560 Buckingham Garden Drive Lithia, FL 33547 1-813-800- TRIO (8746) • info@trioweb.org
    EIN# 251569468

    DISCLAIMER: The content of this TRIO post-transplant cancer Web site is not influenced by sponsors. The site is designed primarily for use by transplant recipients and their supporters. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with your transplant team or a physician skilled in cancer and your organ type if you suspect you are ill.